Saint-Cloud

• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 5 Multiple Myeloma
• AIR. ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS A controlled randomized, open label, multicenter, non-inferiority trial evaluating a … Pending
  2024-516097-30-00 6 Community acquired pneumonia (CAP)
• CANDIDATE THERAPIES IN COMBINATION OR SEQUENTIALLY WITH TYROSINE KINASE INHIBITORS IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) P … Pending
  2024-516328-32-00 4 CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML)
• ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p … Pending
  2024-517285-41-00 5 Newly diagnosed prostate cancer with pelvic lymph nodes metastases
• Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct … Pending
  2024-518139-12-00 4 locally advanced or metastatic Pancreatic ductal adenocarcinoma
• Tucatinib and trastuzumab in HER3-mutant and HER2-not amplified metastatic breast cancer Pending
  2024-519624-24-00 4 HER3-mutant and HER2-not amplified metastatic breast cancer
• Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin ( … Pending
  2025-520995-24-00 5 Adult patients treated for haematological disorders, in whom chemother
• Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w … Pending
  2025-521909-40-00 4 Patients with metastatic or locally advanced HER2-low triple-negative
• A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Pending
  2025-522791-92-00 5 Neoplasm Metastasis
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting
  2025-521884-12-00 5 2026-03-19 First line triple-negative breast cancer (TNBC)
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 5 2023-09-28 marginal zone lymphoma
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) Recruiting
  2024-512358-78-00 7 2015-01-20 Solid Tumors
• Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting
  2025-521805-41-00 5 2026-02-18 Patients with HER2-positive, locally advanced or metastatic breast can
• Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting
  2024-517766-41-00 4 2026-02-17 Patients with metastatic pancreatic ductal adenocarcinoma.
• A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting
  2025-521904-23-00 4 2026-02-17 Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Intravenous Mirvetuximab Soravtansin … Recruiting
  2025-521606-18-00 4 2026-01-29 Ovarian Cancer
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate

Showing 1–24 of 137 trials